Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:ASND
- CUSIP: N/A
- Web: www.ascendispharma.com
- Market Cap: $787.52 million
- Outstanding Shares: 32,502,000
- 50 Day Moving Avg: $27.66
- 200 Day Moving Avg: $24.61
- 52 Week Range: $11.92 - $31.86
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.55
- P/E Growth: -0.31
- Annual Revenue: $4.06 million
- Price / Sales: 193.97
- Book Value: $5.20 per share
- Price / Book: 4.66
- EBIDTA: ($84,980,000.00)
- Net Margins: -1,158.57%
- Return on Equity: -65.92%
- Return on Assets: -58.86%
- Current Ratio: 6.52%
- Quick Ratio: 6.52%
- Average Volume: 35,931 shs.
- Beta: 0.22
- Short Ratio: 8.8
Frequently Asked Questions for Ascendis Pharma A/S (NASDAQ:ASND)
What is Ascendis Pharma A/S's stock symbol?
Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."
How were Ascendis Pharma A/S's earnings last quarter?
Ascendis Pharma A/S (NASDAQ:ASND) released its quarterly earnings results on Tuesday, May, 23rd. The company reported ($0.83) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by $0.19. The business earned $0.40 million during the quarter, compared to analyst estimates of $1.10 million. Ascendis Pharma A/S had a negative net margin of 1,158.57% and a negative return on equity of 65.92%. View Ascendis Pharma A/S's Earnings History.
Where is Ascendis Pharma A/S's stock going? Where will Ascendis Pharma A/S's stock price be in 2017?
5 brokers have issued 12 month price objectives for Ascendis Pharma A/S's stock. Their predictions range from $26.00 to $36.00. On average, they anticipate Ascendis Pharma A/S's stock price to reach $31.00 in the next year. View Analyst Ratings for Ascendis Pharma A/S.
What are analysts saying about Ascendis Pharma A/S stock?
Here are some recent quotes from research analysts about Ascendis Pharma A/S stock:
- 1. According to Zacks Investment Research, "Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. " (5/24/2017)
- 2. Wedbush analysts commented, "The Wedbush View. We see ASND as an attractive investment in the short- and longer-term with pipeline progress and competitor data release in the coming months, plus results from the pivotal heiGHt trial in late 2018. Cash runway into Q4:18. Ascendis reported revenues of €0.37MM and a (loss) of €(0.78)." (5/24/2017)
- 3. Leerink Swann analysts commented, "We project that ASND’s cash position at YE16 will be ~ $180M and expect this will fund operations through completion of its TransCon Growth Hormone study in 2018." (12/1/2016)
Are investors shorting Ascendis Pharma A/S?
Ascendis Pharma A/S saw a drop in short interest in the month of April. As of April 13th, there was short interest totalling 341,859 shares, a drop of 19.2% from the March 31st total of 423,134 shares. Based on an average daily trading volume, of 37,240 shares, the short-interest ratio is currently 9.2 days.
Who are some of Ascendis Pharma A/S's key competitors?
Some companies that are related to Ascendis Pharma A/S include Lexicon Pharmaceuticals (LXRX), Radius Health (RDUS), Array Biopharma (ARRY), Corcept Therapeutics Incorporated (CORT), Repligen (RGEN), Innoviva (INVA), Emergent Biosolutions (EBS), Loxo Oncology (LOXO), Blueprint Medicines Corp (BPMC), Dermira (DERM), Amicus Therapeutics (FOLD), Coherus Biosciences (CHRS), Insys Therapeutics (INSY), Insmed Incorporated (INSM), Xencor (XNCR), Acceleron Pharma (XLRN), Forward Pharma A/S (FWP) and Epizyme (EPZM).
When did Ascendis Pharma A/S IPO?
(ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.
Who owns Ascendis Pharma A/S stock?
Ascendis Pharma A/S's stock is owned by a variety of of institutional and retail investors. Top institutional investors include RA Capital Management LLC (16.69%), FMR LLC (0.00%), EcoR1 Capital LLC (3.16%), VHCP Management II LLC (0.00%), Janus Capital Management LLC (1.72%) and OppenheimerFunds Inc. (0.00%). View Institutional Ownership Trends for Ascendis Pharma A/S.
Who sold Ascendis Pharma A/S stock? Who is selling Ascendis Pharma A/S stock?
Ascendis Pharma A/S's stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management III LLC, Sphera Funds Management LTD., Janus Capital Management LLC, Emory University, Highbridge Capital Management LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Ascendis Pharma A/S.
Who bought Ascendis Pharma A/S stock? Who is buying Ascendis Pharma A/S stock?
Ascendis Pharma A/S's stock was acquired by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Marshall Wace North America L.P., MARSHALL WACE ASIA Ltd, VHCP Management II LLC, FMR LLC, EcoR1 Capital LLC, Eventide Asset Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Ascendis Pharma A/S.
How do I buy Ascendis Pharma A/S stock?
Shares of Ascendis Pharma A/S can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Ascendis Pharma A/S stock cost?
One share of Ascendis Pharma A/S stock can currently be purchased for approximately $24.23.
Earnings History for Ascendis Pharma A/S (NASDAQ:ASND)Earnings History by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/23/2017||Q1||($0.64)||($0.83)||$1.10 million||$0.40 million||View||N/A|
|3/22/2017||Q4||($0.61)||($0.55)||$1.22 million||$1.13 million||View||N/A|
|11/30/2016||Q316||($0.71)||($0.80)||$1.25 million||$1.30 million||View||N/A|
|8/31/2016||Q216||($0.67)||($0.60)||$1.11 million||$1.28 million||View||Listen|
|4/14/2016||Q4 2015||($0.46)||($0.54)||$2.17 million||View||N/A|
|8/24/2015||Q2||($0.48)||($0.70)||$2.23 million||$2.15 million||View||N/A|
|5/18/2015||Q115||($0.39)||$0.07||$2.24 million||$2.38 million||View||Listen|
Earnings Estimates for Ascendis Pharma A/S (NASDAQ:ASND)
2017 EPS Consensus Estimate: ($3.10)
2018 EPS Consensus Estimate: ($3.39)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Ascendis Pharma A/S (NASDAQ:ASND)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Ascendis Pharma A/S (NASDAQ:ASND)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Ascendis Pharma A/S (NASDAQ:ASND)
Latest Headlines for Ascendis Pharma A/S (NASDAQ:ASND)
Ascendis Pharma A/S (ASND) Chart for Sunday, May, 28, 2017